Moderna, biotech stocks slide following resignation of FDA official Peter Marks [Yahoo! Finance Canada]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance Canada
The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term. Marks was the director of the Center for Biologics Evaluation and Research, referred to as CBER, within the FDA. Under his leadership, the FDA approved COVID-19 vaccines during the pandemic as well as the latest RSV (respiratory syncytial virus) vaccines. Moderna, Inc. (MRNA) Vaccine stocks such as Moderna ( MRNA ) fell more than 10% in early trading Monday. In his resignation letter , Marks raised concerns about the anti-vaccine beliefs of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and whether the new FDA head, Marty Makary, would be able to stand up to them. "Efforts currently being advanced by some on the adverse health effects of vaccination are concerning," Marks wrote. "Undermining confidence in well-established vaccines ... is irresponsible, detriment
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) was given a new $28.00 price target on by analysts at Morgan Stanley.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "hold" rating on the stock.MarketBeat
- Global AI Infrastructure Shift Ignites Biotech Growth PhaseGlobeNewswire
- Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 12/16/25 - Form SC
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- MRNA's page on the SEC website